Medication exposure of the dyad patient-caregiver in Alzheimer's disease and related dementias: a cross-sectional study.
Int J Clin Pharm
; 46(1): 205-209, 2024 Feb.
Article
em En
| MEDLINE
| ID: mdl-37532841
ABSTRACT
BACKGROUND:
Patients with Alzheimer's disease and related dementias and their caregivers can be defined as people with higher risk of developing medication-related problems due to aging and polypharmacy.AIM:
To assess the medication exposure of patient with Alzheimer's disease and related dementias and their caregivers.METHOD:
Ancillary cross-sectional study based on baseline medication data of the PHARMAID RCT. The PHARMAID study was a multi-center RCT assessing an integrated pharmaceutical care at a psychosocial program. Older outpatients with Alzheimer's disease and related dementias and their older caregivers were eligible for inclusion. Baseline medication data were used to assess the medication exposure, illustrated by the number of medications, the prevalence of potentially inappropriate medications (PIMs) using the EU(7)-PIM list and the Medication Regimen Complexity Index (MRCI).RESULTS:
Seventy-three dyads were included in this ancillary study. The mean numbers (SD) of medications used by patients was 6.8 (2.6) and by caregivers was 4.7 (3.7). Overall, 60.3% of patients used at least one PIM and 47.9% of caregivers. Regarding the medication regimen complexity, the mean MRCI was 16.3(8.1) for patients and 11.3(10.5) for caregivers.CONCLUSION:
The results of this study confirm the relevance of carrying out medication review with patients, but also with their caregivers who can be considered as hidden patients.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Doença de Alzheimer
Tipo de estudo:
Clinical_trials
/
Observational_studies
/
Prevalence_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Revista:
Int J Clin Pharm
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
França